Robbins LLP Urges ARDX Stockholders to Contact the Firm for Information About the Securities Class Action Against Ardelyx, Inc.

A securities class action has been filed against Ardelyx, Inc. (NASDAQ: ARDX) alleging the company misled investors about its commercial performance and growth prospects for its drug products IBSRELA and XPHOZAH. The lawsuit covers purchases between January 13, 2025 and August 6, 2026. On August 6, 2026, Ardelyx reduced its full-year 2026 IBSRELA revenue guidance and withdrew long-term XPHOZAH guidance due to increased payer access barriers, causing the stock to drop 18% in one day from $4.87 to $4.00 per share.